-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Monthly Archives: March 2011
IP Position Critical to Biotech Investment
A great article from Genetic Engineering and Biotechnology News written by Lisa Haile reviewing the Myriad case and its implications for future medical advances. Interesting Quotes: “While it is unfortunate, I have seen quite a few technologies over the years that would be of potential great benefit to patients, but the intellectual property was simply not there to support protecting the product from fast followers in the market place,” explains Robert More, a general partner Read More >
The Biotech Labeling Debate
What’s in a Label? Responding to a poorly-worded and obviously biased MSNBC Reader Survey about the labeling of foods derived from agricultural biotechnology, the Illinois Farm Bureau posted on its blog an editorial with its own ideas about how to deal with the labeling dilemma. A rose, by any other name, smells just as sweet. Unless it’s genetically modified, if you listen to some of the arguments out there. Last week, MSNBC ran a story about GMO Read More >
Biofuels Digest, BIO Launch Spring 2011 Bioenergy Business Outlook Survey
Biofuels Digest and the Biotechnology Industry Organization (BIO) invite the industry to take part in the Spring 2011 Bioenergy Business Outlook Survey. The survey examines growth expectations and opportunities from a company, national and organizational point of view. It also examines the role of research, government policy, finance, and research and market partners in creating opportunities or barriers to the growth of green jobs, energy security and reductions in greenhouse gas emissions. The survey is Read More >
2011 BIO International Convention Super Sessions
2011 BIO International Convention Super Sessions Focus on State of the Industry C-Level speakers lead broad conversations on global biotech, industry forecast, and key trends WASHINGTON, D.C. (March 2, 2011) — The 2011 BIO International Convention will feature six high-level super sessions focused on the state of the industry, global biotech advancements and the outlook on the future of the industry. Hosted by the Biotechnology Industry Organization (BIO), the global event for biotechnology will take Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: BIO, BIO International Convention, Bio-Innovation Scorecard, Biologics, biotechnology, Biotechnology Industry Organization, Biotechnology Industry Report, Biotechnology Innovation Ecosystem, Biotechnology Trade Expo, Burrill, Campbell Alliance, Dealmakers' Intentions, Eli Lilly and Company, emerging markets, Ernst & Young, Fareed Zakaria, global biotech, Jim Greenwood, Merck, Scientific American, State-of-the-Industry Report, Super Sessions
Tags: BIO, BIO International Convention, Bio-Innovation Scorecard, Biologics, biotechnology, Biotechnology Industry Organization, Biotechnology Industry Report, Biotechnology Innovation Ecosystem, Biotechnology Trade Expo, Burrill, Campbell Alliance, Dealmakers' Intentions, Eli Lilly and Company, emerging markets, Ernst & Young, Fareed Zakaria, global biotech, Jim Greenwood, Merck, Scientific American, State-of-the-Industry Report, Super Sessions
BIO submits comments on Australian Senate Patent Amendment
The Australian Senate has proposed the Patent Amendment (Human Genes and Biological Materials) Bill 2010 that aims to ban ’gene patents’. From the BIO Submission to Australian Senate Legal Committee on Patent Amendment: This amendment would exclude from patent protection “any” biological material, whether a human gene or otherwise, that is substantially identical to a naturally-occuring biological material. Specifically, the amendment states that the following materials would be catergorically declared unpatentable: “biological materials including their components Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: animal healthcare products, antibiotics, Australia, Australian Senate, Australian Senate Legal Committee on Patent Amendment, biological materials, biotechnology, celss, diagnostics, DNA, DNA patents, drugs, environmental mitigation and remediation, Gene Patents, gene patents, Green Technology, human health, insulin, patent, Patent Amendment (Human Genes and Biological Materials) Bill 2010, proteins, renewable energy, RNA, therapeutics
Tags: animal healthcare products, antibiotics, Australia, Australian Senate, Australian Senate Legal Committee on Patent Amendment, biological materials, biotechnology, celss, diagnostics, DNA, DNA patents, drugs, environmental mitigation and remediation, Gene Patents, gene patents, Green Technology, human health, insulin, patent, Patent Amendment (Human Genes and Biological Materials) Bill 2010, proteins, renewable energy, RNA, therapeutics
